CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (VBIV) (VBV.TO) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 common shares, which included 2,100,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares at a price to the public of US$3.05 per share.
Please check future if this stock would fit into your investment portfolio, for a buy at this time. I see $4.00 to $4.20 in short term run. Good luck.
Please check future if this stock would fit into your investment portfolio, for a buy at this time. I see $4.00 to $4.20 in short term run. Good luck.